The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMediumUpdated×3•Originally published 15 April 2026•Updated 17 April 2026•

1 min read

Cosmos Health Reports Record $65.27M Revenue in 2025 with 83% Gross Profit Surge

3D metallic 'PVH' text with 'CALVIN KLEIN' and 'TOMMY HILFIGER' names. Upward trend line, 'EARNINGS BEAT', 'REVENUE: +14%', and '2026 GUIDANCE' on an orange background.

Key Facts

1Cosmos Health reported record revenue of $65.27 million for 2025, a 20% increase year-over-year.

about 2 months ago

Version History

Version 3about 2 months ago

What changed: Updated to include the company's announcement regarding AI integration and its potential to reduce operating expenses by 30%.

Version 2about 2 months ago

What changed: The report was updated to include specific operational metrics regarding SKU expansion, Cana Laboratories manufacturing contracts, the development stage of the CCX0722 weight management product, and the quantification of gross margin expansion in basis points.

Version 1about 2 months ago

What changed: Updated to include the 10x increase in cash reserves, 82% improvement in Adjusted EPS, and the launch of a $300M digital asset treasury strategy.

Cosmos Health Inc. (COSM) reported record 2025 revenue of $65.27 million, driven by an 83% surge in gross profit and significant operational expansion across its Sky Premium Life and Cana Laboratories divisions. In a strategic update, the company announced the integration of AI across its operations, which is projected to decrease certain operating expenses by up to 30%. These AI investments are specifically aimed at enhancing efficiency, reducing costs, and improving customer experience to drive further sales growth. The company's R&D pipeline also remains active with its CCX0722 weight management product entering final development. Despite scaling-related losses, the outlook is supported by a $300 million financing facility and substantial share purchases by CEO Greg Siokas.